Clinical trial

Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation

NCT02477813

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE2

Study timeline

Study start (actual)2015-01-01Date precision: month

Registry last updated2018-11-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer Recurrentunresolved

Interventions

TemozolomideDRUG · verified · RxNorm: temozolomide

Sponsors & collaborators

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02477813 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.